Boceprevir dosing for late responders and null responders: The role of bridging data between treatment‐naïve and ‐experienced subjects

• Published in: Hepatology (Baltimore, Md.) Vol. 57; no. 3; pp. 903 - 907
• Main Authors: Florian, Jeffry, Jadhav, Pravin R., Amur, Shashi, Ayala, Ruben, Harrington, Patrick, Mishra, Poonam, O'Rear, Jules, Pacanowski, Michael, Robertson, Sarah, Singer, Mary, Soon, Greg, Zeng, Wen, Murray, Jeffrey
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2013; Wolters Kluwer Health, Inc
• Subjects: Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Clinical Trials, Phase III as Topic - methods; Drug Approval - methods; Drug Monitoring - methods; Drug Resistance, Viral; Drug Therapy, Combination - standards; Evidence-Based Medicine - methods; Hepatitis C, Chronic - drug therapy; Hepatology; Humans; Interferon-alpha - therapeutic use; Proline - administration & dosage; Proline - analogs & derivatives; Proline - therapeutic use; Ribavirin - therapeutic use; United States; United States